Tolvaptan for polycystic kidney disease trial published in NEJM. Print
NEJM: Conclusions. Tolvaptan, as compared with placebo, slowed the increase in total kidney volume and the decline in kidney function over a 3-year period in patients with ADPKD but was associated with a higher discontinuation rate, owing to adverse events

...